Statistics from Altmetric.com
Idiopathic pulmonary fibrosis (IPF) is an incurable condition characterised by progressive extracellular matrix deposition and tissue remodelling in the adult human lung.1 Because 5-year mortality rates approach 70%, new approaches to treatment are sorely needed. IPF is thought to result from an abnormal wound healing response caused by an unknown insult to the lung epithelium that results in the recruitment and activation of myofibroblasts via incompletely understood mechanisms.1 The contribution of immune activation to these processes remains unknown. While the contribution of innate cell populations such as macrophages is gaining increased acceptance, the contribution of T cell driven adaptive immune responses remain controversial.2 The paper by Milger et al3 represents an important step forward in our understanding of this issue.
Historically, IPF has been defined as a non-immune entity due to its lack of an identifiable antigen driven immune response, lack of inflammatory infiltrate on lung biopsy, lack of benefit from conventional immunosuppressive therapies and lack of a requirement for lymphocytes for development of maximal fibrosis in commonly used animal models.1 2 However, the now seminal finding that lymphocyte modulating agents actually worsen outcomes in IPF4 combined with human and animal data demonstrating an imbalance between T helper populations in these settings suggests a critical role …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.